SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: bill small who wrote (203)3/13/1998 9:50:00 AM
From: targetedmoab  Read Replies (1) | Respond to of 656
 
Bill,
Revenue model of each product especially pipeline drugs is a crap shoot. Many have an untaped potential such as Flt 3 ligand. Enbrel has a potential of a billion but that will be a few years. The products on market now probably figure 15%-20% increase each year......



To: bill small who wrote (203)3/13/1998 3:09:00 PM
From: LJM  Respond to of 656
 
I checked Stragegic Investor and all analysts who follow IMNX had estimated losses through 1999. Nothing is given beyond 1999. I would say that info is useless.

LJM



To: bill small who wrote (203)3/13/1998 3:17:00 PM
From: LJM  Respond to of 656
 
I was in error on my previous post. I looked at it again and of the 9 analysts who follow IMNX. The high for 1998 earnings was .45 cents and the low was (.54) cents. Nothing was reported for 1999 at all.

LJM


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News